Neal Shore, MD, FACS – LUGPA discusses Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
Browsing: Prostate
Neal Shore, MD, FACS – LUGPA discusses Olaparib for Metastatic Castration-Resistant Prostate Cancer
Neal Shore, MD, FACS – LUGPA discusses Olaparib for Metastatic Castration-Resistant Prostate Cancer
Neal Shore, MD, FACS – LUGPA discusses Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
Neal Shore, MD, FACS – LUGPA discusses Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
Nicholas J. Vogelzang, MD Comprehensive Cancer Centers of Nevada discusses CX-2029, a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results…
Huma Q. Rana, MD of Dana Farber Cancer Institute @DanaFarber discusses a randomized controlled trial of video-education or in-person genetic…
Huma Q. Rana, MD of Dana Farber Cancer Institute @DanaFarber discusses a randomized controlled trial of video-education or in-person genetic…
Huma Q. Rana, MD of Dana Farber Cancer Institute @DanaFarber discusses a randomized controlled trial of video-education or in-person genetic…
Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses DARolutamide observationaL study patients in nonmetastatic castration-resistant prostate cancer (nmCRPC)…
Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses darolutamide and enzalutamide effects on physical and neurocognitive function and…
Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses darolutamide and enzalutamide effects on physical and neurocognitive function and…
Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses the safety outcomes of darolutamide versus apalutamide and enzalutamide in…
Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses the safety outcomes of darolutamide versus apalutamide and enzalutamide in…
Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses the overall survival results of phase III ARAMIS study of…
Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses the overall survival results of phase III ARAMIS study of…
Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses the overall survival results of phase III ARAMIS study of…
Andrew Krivoshik, MD of Astellas @AstellasUS discusses the long-term results of the phase III ADMIRAL trial presented at this year’s…
Andrew Krivoshik, MD of Astellas @AstellasUS discusses the importance of the phase III PROSPER trial in the prostate cancer community…
Mark Wildgust, VP of Janssen @JanssenUS discusses ERLEADA (apalutamide) significantly improving overall survival in patients with non-metastatic castration-resistant prostate cancer:…
Mark Wildgust, VP of Janssen @JanssenUS discusses ERLEADA (apalutamide) significantly improving overall survival in patients with non-metastatic castration-resistant prostate cancer:…
Mark Wildgust, VP of Janssen @JanssenUS discusses ERLEADA (apalutamide) significantly improving overall survival in patients with non-metastatic castration-resistant prostate cancer:…
Mark Wildgust, VP of Janssen @JanssenUS discusses ERLEADA (apalutamide) significantly improving overall survival in patients with non-metastatic castration-resistant prostate cancer:…
Mark Wildgust, VP of Janssen @JanssenUS discusses ERLEADA (apalutamide) significantly improving overall survival in patients with non-metastatic castration-resistant prostate cancer:…
Mark Wildgust, VP of Janssen @JanssenUS discusses ERLEADA (apalutamide) significantly improving overall survival in patients with non-metastatic castration-resistant prostate cancer:…
Himisha Beltran, MD of Dana Farber @DanaFarber discusses circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer and…
Himisha Beltran, MD of Dana Farber @DanaFarber discusses circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. How…
Himisha Beltran, MD of Dana Farber @DanaFarber discusses circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. Read…
Earn CME: https://www.naccme.com/program/19-cpc-101-5 This webcast features a presentation by Dr. Atish D. Choudhury that examines the latest clinical safety and…
Ron Peck, MD, CMO of Arvinas @Arvinas on the orally-active proteolysis targeting chimera (PROTAC) molecule being developed to treat men with metastatic…
Ron Peck, MD, CMO of Arvinas @Arvinas answers common questions on the orally-active proteolysis targeting chimera (PROTAC) molecule being developed to treat…
Ron Peck, MD, CMO of Arvinas @Arvinas discusses the initial safety and PK data on an orally-active proteolysis targeting chimera (PROTAC) molecule…
Ron Peck, MD, CMO of Arvinas @Arvinas discusses an orally-active proteolysis targeting chimera (PROTAC) molecule being developed to treat men with metastatic…
Dr. Mark Tuthill, MD of University of Oxford explains the ADVANCE, Phase 2a data, testing VTP-800 on prostate cancer immunotherapy…
Dr. Mark Tuthill, MD of University of Oxford answers the ADVANCE, Phase 2a data, testing VTP-800 on prostate cancer immunotherapy:…
Dr. Mark Tuthill, MD of University of Oxford discusses the ADVANCE, Phase 2a data, testing VTP-800 on prostate cancer immunotherapy.…
Dr. Sumit Subudhi, M.D., Ph.D. of @MDAndersonNews explains the phase II trial in effective immunotherapy with markers of immune activation…
Dr. Sumit Subudhi, M.D., Ph.D. of @MDAndersonNews answers if the markers are predictive of outcomes on immunotherapy with markers of…
Dr. Sumit Subudhi, M.D., Ph.D. of @MDAndersonNews discusses effective immunotherapy with markers of immune activation in metastatic prostate cancer. While…
Neeraj Agarwal, MD @neerajaiims of @huntsmancancer discusses post-hoc review of data from the TITAN Phase 3 trial on time to…
Neeraj Agarwal, MD @neerajaiims of @huntsmancancer discusses post-hoc review of data from the TITAN Phase 3 trial on time to…
Neeraj Agarwal, MD @neerajaiims of @huntsmancancer discusses post-hoc review of data from the TITAN Phase 3 trial on time to…
Neal Shore, MD of Carolina Urologic Research Center @AtlanticUrology explains the randomized phase II study of sipuleucel-T with or without radium-223: how…
Neal Shore, MD of Carolina Urologic Research Center explains the randomized phase II study of sipuleucel-T with or without radium-223…
Neal Shore, MD of Carolina Urologic Research Center explains CBF in regions relevant to cognitive function with ENZA to DARO…
Neal Shore, MD of Carolina Urologic Research Center explains CBF in regions relevant to cognitive function with ENZA to DARO…
Neal Shore, MD of Carolina Urologic Research Center explains cerebral blood flow (CBF) in regions relevant to cognitive function with…
Arlene Siefker-Radtke, MD of @MDAndersonNews answers the phase 1b/2 NORSE study: the importance of mutation testing.
Arlene Siefker-Radtke, MD of @MDAndersonNews answers the phase 1b/2 NORSE study: how this affects clinicians, patients and treatment today.
Arlene Siefker-Radtke, MD of @MDAndersonNews answers the phase 1b/2 NORSE study: does FGFR targeted therapy work better than an immune…